BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 9502078)

  • 1. Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns.
    Allgayer H; Babic R; Grützner KU; Beyer BC; Tarabichi A; Schildberg FW; Heiss MM
    Clin Exp Metastasis; 1998 Jan; 16(1):62-73. PubMed ID: 9502078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical value of extended biologic staging by bone marrow micrometastases and tumor-associated proteases in gastric cancer.
    Heiss MM; Allgayer H; Gruetzner KU; Babic R; Jauch KW; Schildberg FW
    Ann Surg; 1997 Dec; 226(6):736-44; discussion 744-5. PubMed ID: 9409572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems.
    Allgayer H; Babic R; Gruetzner KU; Tarabichi A; Schildberg FW; Heiss MM
    J Clin Oncol; 2000 Jun; 18(11):2201-9. PubMed ID: 10829039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An immunohistochemical assessment of cathepsin D in gastric carcinoma: its impact on clinical prognosis.
    Allgayer H; Babic R; Grützner KU; Beyer BC; Tarabichi A; Wilhelm Schildberg F; Heiss MM
    Cancer; 1997 Jul; 80(2):179-87. PubMed ID: 9217027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system.
    Heiss MM; Babic R; Allgayer H; Gruetzner KU; Jauch KW; Loehrs U; Schildberg FW
    J Clin Oncol; 1995 Aug; 13(8):2084-93. PubMed ID: 7636552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer.
    Nekarda H; Schmitt M; Ulm K; Wenninger A; Vogelsang H; Becker K; Roder JD; Fink U; Siewert JR
    Cancer Res; 1994 Jun; 54(11):2900-7. PubMed ID: 8187075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cysteine and serine proteases in gastric cancer.
    Plebani M; Herszènyi L; Cardin R; Roveroni G; Carraro P; Paoli MD; Rugge M; Grigioni WF; Nitti D; Naccarato R
    Cancer; 1995 Aug; 76(3):367-75. PubMed ID: 8625115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urokinase-type plasminogen activator expression correlates with tumor angiogenesis and poor outcome in gastric cancer.
    Kaneko T; Konno H; Baba M; Tanaka T; Nakamura S
    Cancer Sci; 2003 Jan; 94(1):43-9. PubMed ID: 12708473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High level of urokinase-type plasminogen activator is a new prognostic marker in patients with gastric carcinoma.
    Cho JY; Chung HC; Noh SH; Roh JK; Min JS; Kim BS
    Cancer; 1997 Mar; 79(5):878-83. PubMed ID: 9041148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus.
    Nekarda H; Schlegel P; Schmitt M; Stark M; Mueller JD; Fink U; Siewert JR
    Clin Cancer Res; 1998 Jul; 4(7):1755-63. PubMed ID: 9676852
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
    Grøndahl-Hansen J; Christensen IJ; Rosenquist C; Brünner N; Mouridsen HT; Danø K; Blichert-Toft M
    Cancer Res; 1993 Jun; 53(11):2513-21. PubMed ID: 8388317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prognostic value of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx].
    Zhao E; Han D; Yu Z; Fan E; Li Y; Zhou Z
    Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2002 Nov; 16(11):599-602. PubMed ID: 15515548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
    Jänicke F; Pache L; Schmitt M; Ulm K; Thomssen C; Prechtl A; Graeff H
    Cancer Res; 1994 May; 54(10):2527-30. PubMed ID: 8168072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of low-risk node-negative breast cancer patients by tumor biological factors PAI-1 and cathepsin L.
    Thomssen C; Oppelt P; Jänicke F; Ulm K; Harbeck N; Höfler H; Kuhn W; Graeff H; Schmitt M
    Anticancer Res; 1998; 18(3C):2173-80. PubMed ID: 9703780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protease levels in breast, ovary, and other gynecological tumor tissues: prognostic importance in breast cancer.
    Ruppert C; Ehrenforth S; Scharrer I; Halberstadt E
    Cancer Detect Prev; 1997; 21(5):452-9. PubMed ID: 9307848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
    Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
    Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.
    Foekens JA; Schmitt M; van Putten WL; Peters HA; Kramer MD; Jänicke F; Klijn JG
    J Clin Oncol; 1994 Aug; 12(8):1648-58. PubMed ID: 8040677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse.
    Harbeck N; Thomssen C; Berger U; Ulm K; Kates RE; Höfler H; Jänicke F; Graeff H; Schmitt M
    Breast Cancer Res Treat; 1999 Mar; 54(2):147-57. PubMed ID: 10424405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer.
    Grøndahl-Hansen J; Peters HA; van Putten WL; Look MP; Pappot H; Rønne E; Dano K; Klijn JG; Brünner N; Foekens JA
    Clin Cancer Res; 1995 Oct; 1(10):1079-87. PubMed ID: 9815897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression and significance of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx].
    Zhao EM; Han DM; Yu ZK; Fan EZ; Li Y
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 2003 Feb; 38(1):39-42. PubMed ID: 12778766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.